DK1007055T3 - Anvendelse af amifostin - Google Patents

Anvendelse af amifostin

Info

Publication number
DK1007055T3
DK1007055T3 DK98906688T DK98906688T DK1007055T3 DK 1007055 T3 DK1007055 T3 DK 1007055T3 DK 98906688 T DK98906688 T DK 98906688T DK 98906688 T DK98906688 T DK 98906688T DK 1007055 T3 DK1007055 T3 DK 1007055T3
Authority
DK
Denmark
Prior art keywords
compounds
aminoalkyl
amifostine
adverse
patients
Prior art date
Application number
DK98906688T
Other languages
English (en)
Inventor
Martin Stogniew
Philip S Schein
Original Assignee
Medimmune Oncology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune Oncology Inc filed Critical Medimmune Oncology Inc
Application granted granted Critical
Publication of DK1007055T3 publication Critical patent/DK1007055T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • AIDS & HIV (AREA)
  • Biochemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Insulating Materials (AREA)
DK98906688T 1997-02-12 1998-02-11 Anvendelse af amifostin DK1007055T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/798,840 US6051563A (en) 1997-02-12 1997-02-12 Methods for the administration of amifostine and related compounds
PCT/US1998/003614 WO1998034622A1 (en) 1997-02-12 1998-02-11 Methods for the administration of amifostine

Publications (1)

Publication Number Publication Date
DK1007055T3 true DK1007055T3 (da) 2004-06-07

Family

ID=25174410

Family Applications (1)

Application Number Title Priority Date Filing Date
DK98906688T DK1007055T3 (da) 1997-02-12 1998-02-11 Anvendelse af amifostin

Country Status (11)

Country Link
US (3) US6051563A (da)
EP (1) EP1007055B1 (da)
JP (1) JP2001512447A (da)
AT (1) ATE258797T1 (da)
AU (1) AU750591B2 (da)
CA (2) CA2625727A1 (da)
DE (1) DE69821498T2 (da)
DK (1) DK1007055T3 (da)
ES (1) ES2216271T3 (da)
PT (1) PT1007055E (da)
WO (1) WO1998034622A1 (da)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6753006B1 (en) 1993-02-22 2004-06-22 American Bioscience, Inc. Paclitaxel-containing formulations
US6573253B2 (en) * 1997-02-12 2003-06-03 Medimmune Oncology Inc. Methods for the administration of amifostine and related compounds
US6051563A (en) * 1997-02-12 2000-04-18 U.S. Bioscience, Inc. Methods for the administration of amifostine and related compounds
US5994409A (en) * 1997-12-09 1999-11-30 U.S. Bioscience, Inc. Methods for treatment of neuro--and nephro--disorders and therapeutic toxicities using aminothiol compounds
US6239119B1 (en) * 1998-04-27 2001-05-29 Medimmune Oncology, Inc. Topical administration of amifostine and related compounds
US6407278B2 (en) * 1998-11-16 2002-06-18 Medimmune Oncology, Inc. Stable amorphous amifostine compositions and methods for the preparation and use of the same
US6384259B1 (en) * 1998-11-16 2002-05-07 Medimmune Oncology, Inc. Stable amorphous amifostine compositions and dosage form
EP1328253B1 (en) * 2000-04-26 2006-03-22 Oregon Health Sciences University Administration of a thiol-based chemoprotectant compound
US7053072B2 (en) 2001-05-11 2006-05-30 Medimmune Oncology, Inc. Methods for the administration of amifostine and related compounds
US20030054042A1 (en) * 2001-09-14 2003-03-20 Elaine Liversidge Stabilization of chemical compounds using nanoparticulate formulations
EP1490030B2 (en) * 2002-03-20 2010-07-14 Elan Pharma International Limited Nanoparticulate compositions of angiogenesis inhibitors
US20080220075A1 (en) * 2002-03-20 2008-09-11 Elan Pharma International Ltd. Nanoparticulate compositions of angiogenesis inhibitors
US7629333B2 (en) 2002-03-29 2009-12-08 Medimmune, Llc Stable amorphous amifostine compositions and methods for the preparation and use of same
EP1809272A4 (en) * 2004-10-18 2008-01-02 Maroon Biotech Corp METHOD AND COMPOSITIONS FOR TREATING DAMAGES THROUGH FREE RADICALS
PT2453910T (pt) * 2009-07-15 2016-12-07 Portola Pharm Inc Formulação de dose unitária de antídoto contra inibidores de fator xa para uso na prevenção de sangramento
CN103336902B (zh) * 2013-06-27 2016-01-13 西安交通大学 一种基于模拟分布平衡血药浓度的药物绝对生物利用度检测方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3892824A (en) * 1968-12-16 1975-07-01 Southern Res Inst S-{107 -({107 -aminoalkylamino)alkyl dihydrogen phosphorothioates
EP0409845A4 (en) * 1988-02-23 1991-07-03 U.S. Bioscience Method for protection from chemotherapeutic side effects
US5424471A (en) * 1992-07-31 1995-06-13 U.S. Bioscience, Inc. Crystalline amifostine compositions and methods of the preparation and use of same
SG47101A1 (en) 1992-07-31 1998-03-20 Us Bioscience Crystalline amifostine compositions and methods for the preparation and use of same
WO1994005299A1 (fr) * 1992-09-04 1994-03-17 Fuji Kagaku Kogyo Kabushiki Kaisha Compositions medicinales
ATE216425T1 (de) * 1994-08-13 2002-05-15 Roche Diagnostics Gmbh Verwendung von interferon-gamma zur vermeidung der proliferation und differenzierung der primitiven hämapoietischen vorläuferzellen
US5846958A (en) * 1995-02-17 1998-12-08 U.S. Bioscience, Inc. Methods of using aminothiols to promote hematopoietic progenitor cell growth
US6051563A (en) * 1997-02-12 2000-04-18 U.S. Bioscience, Inc. Methods for the administration of amifostine and related compounds

Also Published As

Publication number Publication date
EP1007055A4 (en) 2002-05-29
CA2280773C (en) 2008-07-22
ES2216271T3 (es) 2004-10-16
DE69821498D1 (de) 2004-03-11
US6051563A (en) 2000-04-18
EP1007055B1 (en) 2004-02-04
AU6184998A (en) 1998-08-26
US6218377B1 (en) 2001-04-17
ATE258797T1 (de) 2004-02-15
US6127351A (en) 2000-10-03
PT1007055E (pt) 2004-06-30
AU750591B2 (en) 2002-07-25
DE69821498T2 (de) 2004-12-02
JP2001512447A (ja) 2001-08-21
EP1007055A1 (en) 2000-06-14
CA2625727A1 (en) 1998-08-13
WO1998034622A1 (en) 1998-08-13
CA2280773A1 (en) 1998-08-13

Similar Documents

Publication Publication Date Title
DK1007055T3 (da) Anvendelse af amifostin
TR200003635T2 (tr) Peg-IFN-ALFA ve ribavirinin kronik hepatit C tedavisinde kullanılması.
WO1999064059A3 (en) Use of secretin for the treatment of autism and other neurological, behavioral and immunological disorders
DK1870103T3 (da) Anvendelse af uridin i kombination med cholin i behandling af hukommelsesforsstyrrelse
EP1537861A3 (en) Use of aminothiol compounds for the treatment xerostomia caused by therapeutic agents or radiation
BR9809425A (pt) Conjugados alfa interferon-polietilenoglicol para terapia de infecção
GB2368283A (en) Cyclobenzaprine for treating generalized anxiety disorder and compositions thereof
DK1163349T3 (da) Medicinske præparater til behandling af alfa-galactosidase A-mangel
DE60121988D1 (de) Kombinationstherapie mit antidiabetischen und antikonvulsiven mitteln
DK0998287T3 (da) Anvendelse af levobupivacain
DK0959888T3 (da) Anvendelse af det chelerende middel clioquinol til fremstillingen af et farmaceutisk præparat til behandlingen af Alzheimer&#39;s sygdom
BR0116519B1 (pt) cartucho de hemodiafiltraÇço/hemofiltraÇço de diluiÇço intermediÁria.
DK1604674T3 (da) Anvendelse af myoblaster til fremstilling af et medikament til behandling af stressinkontinens
EA200400548A1 (ru) Лечение тяжёлой пневмонии путём введения ингибитора пути тканевого фактора (tfpi)
ATE372774T1 (de) Medikament zur verabreichung von amifostin und verwandten wirkstoffen
TR200001288T2 (tr) Östrojen yoksunluğu sendromunun tedavisinde faydalı 2-arilbenzo (b) tiyofenler.
DE69808440D1 (de) Verwendung von (+)mefloquine zur behandlung von malaria
MXPA03001081A (es) Medicamento anti-inflamatorio.
DK1037629T3 (da) Kombination af et retinsyremetabolismeblokerende middel og en tocopherol
NZ514911A (en) Use of N-acetylcysteine for the preparation of a medicament suitable for the intravenous administration to prevent oxidative stress in dialysed patients
DE69018099D1 (de) Polyamin-Derivate als antineoplastische Mittel.
DE60006284D1 (de) Arzneimittel zur behandlung konvulsivischer zustände
TR200000728T2 (tr) Kronik hepatit C&#39; nin tedavisinde IFN-alfa ve amantadin kullanımı.
BR9907195A (pt) &#34; formulações de tiagabina de liberação prolongada com efeitos colaterais reduzidos &#34;
DK0458537T3 (da) Anvendelse af en terapeutisk forbindelse til behandling af bronkitis